Voriconazole for Invasive Aspergillosis

Primary Treatment Regimen

The Infectious Diseases Society of America recommends voriconazole as the first-line treatment for invasive aspergillosis, with superior efficacy and survival compared to alternative agents, based on a landmark randomized trial demonstrating 52.8% successful outcomes at 12 weeks versus 31.6% with amphotericin B deoxycholate, and 12-week survival was 70.8% with voriconazole compared to 57.9% with amphotericin B (hazard ratio 0.59), representing a significant mortality benefit, with A-I level evidence 1
The American College of Clinical Infectious Diseases recommends voriconazole as the standard of care for invasive aspergillosis, based on a randomized trial showing similar efficacy between two liposomal amphotericin B doses, establishing it as a viable alternative primary therapy 1

The Infectious Diseases Society of America recommends liposomal amphotericin B 3-5 mg/kg/day IV as the alternative first-line therapy for patients with voriconazole contraindications or intolerance, based on a randomized trial showing similar efficacy between two L-AmB doses, establishing it as a viable alternative primary therapy 1, 2, 3
The European Society of Clinical Microbiology and Infectious Diseases recommends switching to liposomal amphotericin B for isolates with voriconazole MIC >2 mg/L, and considering combination therapy with an echinocandin or L-AmB monotherapy for isolates with voriconazole MIC = 2 mg/L (intermediate) 4

The Clinical Infectious Diseases society recommends exercising caution with IV voriconazole in patients with renal insufficiency due to accumulation of the sulfobutyl-ether cyclodextrin vehicle, which is renally cleared, and considering oral formulation in renal impairment if patient can tolerate oral medications 5, 6
The Clinical Infectious Diseases society recommends reducing maintenance dose in patients with hepatic impairment, as voriconazole is hepatically metabolized with minimal renal excretion 6

The Clinical Microbiology and Infection society recommends therapeutic drug monitoring for voriconazole due to highly variable pharmacokinetics, with target trough concentrations of 1-4 mg/L (measured by HPLC) during treatment of invasive aspergillosis 3, 4

The Infectious Diseases Society of America recommends considering salvage therapy options, including lipid formulations of amphotericin B (A-II recommendation), posaconazole (B-II recommendation), itraconazole (B-II recommendation), and caspofungin or micafungin (B-II recommendation), when voriconazole fails, with the key principle of changing drug class when voriconazole fails—switching from azole to polyene or echinocandin rather than to another azole 1, 2

The Infectious Diseases Society of America recommends a loading dose of 6 mg/kg IV every 12 hours for the first 24 hours, followed by a maintenance dose of 4 mg/kg IV every 12 hours, for immunocompromised patients with invasive aspergillosis 7, 8
The standard maintenance dose is 4 mg/kg IV every 12 hours after the loading phase, as recommended by the Clinical Infectious Diseases and Journal of Microbiology, Immunology and Infection 7, 8
The standard oral maintenance dose is 200 mg orally every 12 hours, as recommended by the Clinical Infectious Diseases and Journal of Microbiology, Immunology and Infection 7, 8

The Infectious Diseases Society of America recommends treatment for a minimum of 6-12 weeks and throughout the period of immunosuppression until lesions resolve, with a minimum of 6 weeks of IV treatment 7
Reversal of immunosuppression is critical for favorable outcomes, as stated by the Clinical Infectious Diseases 7

Particular caution is needed with anticonvulsants in CNS aspergillosis, as significant bidirectional interactions occur, as reported by the Journal of Microbiology, Immunology and Infection 9